The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric (T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution. The clinical rationale for the proposed studies is that prostate cancer management, more than many cancers, requires accurate imaging information to select the most appropriate treatment for individual patients and for assessing response to therapy. This is due to the pathologic and biologic complexity of the human prostate and prostate cancer. This complexity results in questions of whether and how to treat individual prostate cancer patients. Additionally, this complexity demands state-of-the-art high spatial resolution multiparametric MR imaging and spectroscopy techniques to accurately assess disease status in individual patients. While recent advances in the development of anatomic, metabolic and physiologic imaging methods are having a significant impact in clinical prostate cancer research studies, a robust commercially available multiparametric 3T (T2 MRI, 1H MRSI, DTI, and DCE) magnetic resonance imaging exam does not exist. In this project, we also propose to develop and translate into patient studies hyperpolarized 13C MR, a new metabolic imaging technique that has shown potential for greatly advancing prostate cancer imaging. The proton MR techniques have been developed through an NCI-funded Bioengineering Research Partnership development project and are now ready for clinical validation studies. The hyperpolarized 13C MR is at an earlier developmental stage nearing patient studies and now requires this academic-industrial partnership with both extensive MR engineering and clinical expertise to move this promising new metabolic imaging technology forward for patient evaluation studies. This academic-industrial partnership between a major MR manufacturer and an experienced prostate cancer clinical-research group is critical for the creation of new clinical imaging tools for better characterizing the presence, extent, aggressiveness, and response to therapy of this very common and biologically diverse cancer.

Public Health Relevance

The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric (T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution and use in multi-center clinical trials. The clinical rationale is that prostate cancers demonstrate a tremendous range in biologic diversity, and an urgent need exists to develop non-invasive imaging biomarkers for improved prostate cancer patient-specific treatment planning and early assessment of therapeutic failure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA137207-04
Application #
8507468
Study Section
Special Emphasis Panel (ZRG1-SBIB-U (50))
Program Officer
Menkens, Anne E
Project Start
2010-08-09
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$495,937
Indirect Cost
$174,942
Name
University of California San Francisco
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Salgaonkar, Vasant A; Prakash, Punit; Rieke, Viola et al. (2014) Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys 41:033301
Chang, Stephanie T; Westphalen, Antonio C; Jha, Priyanka et al. (2014) Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy. J Magn Reson Imaging 39:519-25
Flavell, Robert R; Westphalen, Antonio C; Liang, Carmin et al. (2014) Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance. Abdom Imaging 39:1027-35
Muller, Berrend G; Futterer, Jurgen J; Gupta, Rajan T et al. (2014) The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int 113:218-27
Jung, Adam J; Westphalen, Antonio C; Kurhanewicz, John et al. (2014) Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. J Magn Reson Imaging 40:314-23
Zhang, V Y; Westphalen, A; Delos Santos, L et al. (2014) The role of metabolic imaging in radiation therapy of prostate cancer. NMR Biomed 27:100-11
Starobinets, Olga; Guo, Richard; Simko, Jeffry P et al. (2014) Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging 39:1223-9
Tiwari, Pallavi; Kurhanewicz, John; Madabhushi, Anant (2013) Multi-kernel graph embedding for detection, Gleason grading of prostate cancer via MRI/MRS. Med Image Anal 17:219-35
Hsu, Charles C; Hsu, Howard; Pickett, Barby et al. (2013) Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 85:370-7
Tiwari, P; Viswanath, S; Kurhanewicz, J et al. (2012) Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection. NMR Biomed 25:607-19